金融界消息 截至2025年7月30日收盘，塞力医疗（603716）报收于30.89元，下跌2.31%，换手率 23.26%，成交量44.43万手，成交金额13.85亿元。 通过天眼查大数据分析，塞力斯医疗科技集团股份有限公司共对外投资了70家企业，参与招投标项目 146次，知识产权方面有商标信息9条，专利信息7条，此外企业还拥有行政许可26个。 来源：金融界 塞力医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少40.75%，归属净利 润1432.09万元，同比减少553.66%，扣非净利润2846.33万元，同比减少3228.81%，流动比率1.931、速 动比率1.591、资产负债率58.57%。 天眼查商业履历信息显示，塞力斯医疗科技集团股份有限公司，成立于2004年，位于武汉市，是一家以 从事研究和试验发展为主的企业。企业注册资本19095.2305万人民币，实缴资本3800万人民币。公司法 定代表人为温伟。 资金流向方面，今日主力资金净流出3940.25万元，占比成交额2.85%。其中，超大单净流出1123.14万 元、占成交额0.81%，大单净流出2817.11万元、占 ...

金融界消息 截至2025年7月30日收盘，麦迪科技（603990）报收于15.95元，下跌0.62%，换手率 5.47%，成交量16.76万手，成交金额2.64亿元。 资金流向方面，今日主力资金净流出3779.26万元，占比成交额14.34%。其中，超大单净流出2410.14万 元、占成交额9.15%，大单净流出1369.11万元、占成交额5.2%，中单净流出流入377.47万元、占成交额 1.43%，小单净流入3401.78万元、占成交额12.91%。 麦迪科技最新一期业绩显示，截至2025一季报，公司营业总收入6334.00万元、同比减少43.13%，归属 净利润2359.59万元，同比增长138.55%，扣非净利润252.66万元，同比增长103.42%，流动比率2.954、 速动比率2.817、资产负债率34.04%。 通过天眼查大数据分析，苏州麦迪斯顿医疗科技股份有限公司共对外投资了9家企业，参与招投标项目 3028次，知识产权方面有商标信息84条，专利信息168条，此外企业还拥有行政许可17个。 来源：金融界 天眼查商业履历信息显示，苏州麦迪斯顿医疗科技股份有限公司，成立于2009年，位于苏州市， ...

Core Viewpoint - The financial performance of Madi Technology (麦迪科技) shows a significant decline in revenue while net profit has increased substantially, indicating a potential shift in operational efficiency or cost management strategies [1]. Financial Performance - As of the first quarter of 2025, the company reported total revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1]. - The net profit attributable to shareholders was 23.60 million yuan, reflecting a year-on-year increase of 138.55% [1]. - The non-recurring net profit was 2.53 million yuan, showing a year-on-year growth of 103.42% [1]. - The current ratio was 2.95, and the quick ratio was 2.82, indicating strong liquidity [1]. - The debt-to-asset ratio stood at 34.04%, suggesting a moderate level of financial leverage [1]. Market Activity - As of July 29, 2025, Madi Technology's stock closed at 16.05 yuan, with a slight increase of 0.19% [1]. - The trading volume was 138,500 hands, with a total transaction value of 222 million yuan [1]. - There was a net outflow of main funds amounting to 42.94 million yuan, which accounted for 19.32% of the transaction value [1]. - Large orders saw a net outflow of 30.92 million yuan, representing 13.91% of the transaction value [1]. Company Background - Madi Technology, officially known as Suzhou Madi Medical Technology Co., Ltd., was established in 2009 and is located in Suzhou [2]. - The company focuses primarily on research and experimental development, with a registered capital of 3,062.83 million yuan and a paid-in capital of 891.95 million yuan [2]. - The legal representative of the company is Weng Kang [1]. Investment and Intellectual Property - Madi Technology has made investments in 9 companies and participated in 3,027 bidding projects [2]. - The company holds 84 trademark registrations and 168 patents, along with 17 administrative licenses [2].

1. 7月29日(周二)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.13%，标普500指数期货涨0.30%，纳指期货涨0.47%。 | ■ US 30 | 44,896.50 | 44,950.00 | 44,793.00 | +58.90 | +0.13% | | --- | --- | --- | --- | --- | --- | | ■ US 500 | 6,409.10 | 6,409.60 | 6,391.10 | +19.30 | +0.30% | | 틀 US Tech 100 | 23,466.30 | 23,469.40 | 23,366.40 | +110.00 | +0.47% | 2. 截至发稿，德国DAX指数涨1.17%，英国富时100指数涨0.55%，法国CAC40指数涨1.10%，欧洲斯托克50指数涨1.02%。 | 德國DAX30 | 24,223.47 | 24,309.91 | 24,027.94 | +278.96 | +1.17% | | --- | --- | --- | --- | --- | --- | | * 英國富時100 | 9,131.52 ...

Group 1 - The World Artificial Intelligence Conference was held in Shanghai from July 26 to 28, focusing on the theme "Intelligent Era, Common Ball Cooperation" and featured over 1,200 guests from more than 30 countries [1] - The conference aimed to explore the boundaries of future technology and promote innovation in the field of artificial intelligence [1] - The event included a structured agenda with an opening ceremony, high-level global governance meetings, plenary sessions, and numerous forums [1] Group 2 - AI technology has penetrated the entire healthcare service chain, enhancing quality and efficiency from early screening to precision treatment and drug development [2] - The AI Solutions for SME report was released, showcasing classic experiences of AI empowerment for small and medium enterprises, with "Dr.GPT" from the company highlighted as a benchmark in the healthcare sector [5] - The company has integrated AI technology into its strategy, developing a proprietary AI technology stack called AIcare, which covers health management, medical diagnosis assistance, insurance service optimization, and health education [5] Group 3 - The company launched the "Dr.GPT" model, which features multimodal interaction and clinical reasoning capabilities, focusing on intelligent consultation, personalized health management, chronic disease monitoring, and psychological counseling [6] - "Dr.GPT" enhances the diagnostic capabilities of healthcare professionals and provides pre-analysis capabilities to assist in case organization and data analysis [6] Group 4 - The company collaborated with various stakeholders to initiate the "Joint Initiative for Co-building and Sharing AI Agent Protocol," aiming to promote standardization and innovation in the AI industry [7] - The International Cooperation Forum on AI Standardization was held to foster global dialogue and cooperation in AI standardization, focusing on technology co-creation and industry symbiosis [7] Group 5 - The company plans to continue promoting AI+healthcare inclusivity and advance discussions on autonomous AI agent protocol standards, contributing to the "Healthy China" strategy [8]

Core Viewpoint - The healthcare sector is undergoing a profound transformation driven by AI technology, which is deeply integrating into the entire diagnostic and treatment process, leading to significant changes in the industry [1][2]. Group 1: AI Integration in Healthcare - AI is being applied in various areas such as intelligent triage, imaging analysis, and drug development, significantly enhancing the efficiency of medical services [1]. - In Zhejiang, the Wuzhen Smart Hospital has received thousands of patients with fewer than 10 doctors and a number of intelligent triage robots since its opening last year [1]. - An AI medical model developed by a team in Shanghai has successfully "passed" the national medical practitioner qualification exam, showcasing the potential of AI in medical training [1]. - The application of the "Taichu" model at Peking Union Medical College Hospital is expected to reduce the average diagnosis time for rare diseases from over 4 years to about 1 month [1]. Group 2: Human Element in Medicine - The essence of medical service revolves around human care, emphasizing that the core of healthcare should always focus on "people" [1][2]. - Despite advancements in technology, there is an increasing demand for humanized medical care, as patients seek emotional support and understanding from healthcare providers [2]. - Research from Johns Hopkins University indicates that increasing communication time between doctors and patients by 30% can enhance treatment adherence by 50% [2]. Group 3: Balancing Technology and Humanity - AI can make knowledge-based judgments but cannot replace emotional understanding, highlighting the need for a balance between technology and human interaction in medical decision-making [3]. - The risk of allowing technology to dominate the diagnostic process could lead to a deterioration of the doctor-patient relationship, emphasizing the importance of empathy and trust [3]. - A case study illustrates that while AI can suggest optimal treatment based on data, the final decision must consider the patient's personal wishes and emotional state [3]. Group 4: Preserving Medical Humanities - There is a need to prevent "technological dependence" from weakening the transmission of medical humanities, which are essential for maintaining the spirit of medicine [4]. - The warmth and human touch in medical practice, such as the way bad news is delivered or considering a patient's financial situation before tests, cannot be programmed into AI [4]. - The evolution of medical training should not shift solely towards algorithm optimization, as this could lead to a loss of the essential human elements in healthcare [4].

Core Viewpoint - The company has completed the repurchase and cancellation of certain restricted stocks as part of its 2024 stock incentive plan, following the departure of some incentive targets and failure to meet performance targets for the first release period. Group 1: Stock Repurchase and Cancellation - The company repurchased and canceled 138,020 shares of restricted stock at a price of 18.09 yuan per share, totaling approximately 24,967,818 yuan, funded by its own resources [1][6][5] - The repurchase was necessitated by the departure of 8 incentive targets and the failure to meet the performance criteria for the first release period, which required a net profit of at least 20 million yuan for 2024 [3][8] Group 2: Approval Process - The company held multiple board and supervisory meetings to approve the stock incentive plan and its amendments, with the latest approvals occurring on April 25, 2024, and May 21, 2024 [2][3] - The supervisory board confirmed the list of incentive targets and the public notice period did not receive any objections [2][3] Group 3: Impact on Company Structure - Following the repurchase, the company's total registered capital decreased to 264,975,900 yuan, with the total number of shares reduced to 264,975,900 [6][7] - The shareholding structure remains compliant with listing requirements, and the controlling shareholder's status has not changed [7][6] Group 4: Future Performance Conditions - The performance conditions for the release of restricted stocks are set for the years 2024 to 2026, with required net profits of 20 million yuan, 30 million yuan, and 40 million yuan respectively for each year [8]

Group 1: IPO Performance Overview - Seven companies went public last week, including one small IPO and five SPACs submitting initial applications [1][7] - NIQ Global Intelligence priced its IPO below the midpoint, raising $1.1 billion at a market cap of $6.2 billion, but saw a 6% decline in stock price [1][5] - Accelerant's IPO was priced above the range, raising $724 million at a market cap of $4.7 billion, with a stock price increase of 42% [1][5] Group 2: Company Highlights - McGraw Hill's IPO was priced below the range, raising $415 million with a market cap of $3.3 billion, and experienced a 1% drop in stock price [2][5] - Carlsmed raised $101 million at a market cap of $430 million, with a 3% decline in stock price [2][5] - Dreamland's IPO was priced at the lower end, raising $8 million with a market cap of $124 million, and saw a 6% drop in stock price [3][5] Group 3: Emerging Companies - Cre8 Enterprise raised $96 million at a market cap of $6 million, with a 9% increase in stock price [3][5] - Linkhome Holdings raised $6 million at a market cap of $64 million, experiencing a significant stock price increase of 158% [4][5] - Hillhouse Frontier Holdings submitted an initial application for a small IPO, targeting $6 million with a market cap of $106 million [7] Group 4: Upcoming IPOs - Figma plans to raise $979 million with a projected market cap of $15.9 billion, focusing on browser-based design software [9][11] - Shoulder Innovations aims to raise $100 million with a market cap of $432 million, providing advanced implant systems for shoulder surgeries [10][11] - Ambiq Micro plans to raise $80 million with a market cap of $435 million, specializing in ultra-low power semiconductor solutions [10][11]

Summary of Key Points Group 1: Recent IPOs - Last week, 7 new stocks were listed, with 4 raising over $100 million [1] - NIQ Global Intelligence (NIQ) raised $1.05 billion by issuing 50 million shares at $21 each [1] - Accelerant (ARX) raised $724 million by issuing 34.46 million shares at $21 each [1] - McGraw Hill (MH) raised $415 million by issuing 24.39 million shares at $17 each [1] - Carlsmed (CARL) raised $101 million by issuing 6.7 million shares at $15 each [1] Group 2: Upcoming IPOs - Ambiq Micro, a semiconductor company, plans to go public on July 30, 2025, on NYSE under the ticker AMBQ, aiming to raise up to $85 million by issuing 3.4 million shares at $22 to $25 each [5][6] - Figma, a design tool company, plans to go public on July 31, 2025, on NYSE under the ticker FIG, aiming to raise up to $1.034 billion by issuing 36.94 million shares at $25 to $28 each [7][8] - Shoulder Innovations, a medical technology company, plans to go public on July 31, 2025, on NYSE under the ticker SI, aiming to raise up to $105 million by issuing 5 million shares at $19 to $21 each [10]

Trading Information Summary - On July 25, 2025, Sely Medical (603716) closed at 31.22 yuan, up 2.7%, with a turnover rate of 34.88% and a trading volume of 666,300 shares, amounting to a total transaction value of 2.147 billion yuan [1] - The net inflow of main funds was 70.7018 million yuan, accounting for 3.29% of the total transaction value, while retail investors had a net inflow of 665,500 yuan, representing 0.03% of the total [1][3] Company Announcement Summary - Sely Medical announced that its stock price had deviated by more than 20% over three consecutive trading days, indicating abnormal trading activity. The company confirmed that there were no undisclosed significant information from its controlling shareholder and actual controller [1] - The company expects a net profit attributable to shareholders for the first half of 2025 to be between -55 million and -66 million yuan [1] - The controlling shareholder has a high cumulative pledge ratio, which investors should be aware of [1] - The joint venture, Huajiyuan Biotech's therapeutic vaccine project HJY-ATRQβ-001, received acceptance for clinical trial application from the National Medical Products Administration on June 6, 2025, but the success of subsequent clinical trials remains uncertain [1]